Logo image of PDEX

PRO-DEX INC (PDEX) Stock Fundamental Analysis

NASDAQ:PDEX - Nasdaq - US74265M2052 - Common Stock - Currency: USD

46.22  -1.6 (-3.35%)

After market: 46.22 0 (0%)

Fundamental Rating

6

Overall PDEX gets a fundamental rating of 6 out of 10. We evaluated PDEX against 187 industry peers in the Health Care Equipment & Supplies industry. PDEX has an average financial health and profitability rating. PDEX is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one! These ratings would make PDEX suitable for growth investing!


Dividend Valuation Growth Profitability Health

Quickly go to:

6

1. Profitability

1.1 Basic Checks

In the past year PDEX was profitable.
PDEX had a negative operating cash flow in the past year.
Each year in the past 5 years PDEX has been profitable.
The reported operating cash flow has been mixed in the past 5 years: PDEX reported negative operating cash flow in multiple years.
PDEX Yearly Net Income VS EBIT VS OCF VS FCFPDEX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M -10M

1.2 Ratios

Looking at the Return On Assets, with a value of 14.58%, PDEX belongs to the top of the industry, outperforming 96.26% of the companies in the same industry.
PDEX has a better Return On Equity (26.55%) than 96.26% of its industry peers.
Looking at the Return On Invested Capital, with a value of 19.83%, PDEX belongs to the top of the industry, outperforming 98.93% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for PDEX is above the industry average of 7.89%.
The last Return On Invested Capital (19.83%) for PDEX is above the 3 year average (11.81%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 14.58%
ROE 26.55%
ROIC 19.83%
ROA(3y)9%
ROA(5y)12.39%
ROE(3y)15.75%
ROE(5y)22.01%
ROIC(3y)11.81%
ROIC(5y)13.41%
PDEX Yearly ROA, ROE, ROICPDEX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 20 30

1.3 Margins

With an excellent Profit Margin value of 14.61%, PDEX belongs to the best of the industry, outperforming 92.51% of the companies in the same industry.
PDEX's Profit Margin has declined in the last couple of years.
PDEX has a Operating Margin of 18.24%. This is amongst the best in the industry. PDEX outperforms 90.91% of its industry peers.
In the last couple of years the Operating Margin of PDEX has declined.
PDEX's Gross Margin of 31.36% is on the low side compared to the rest of the industry. PDEX is outperformed by 74.33% of its industry peers.
In the last couple of years the Gross Margin of PDEX has declined.
Industry RankSector Rank
OM 18.24%
PM (TTM) 14.61%
GM 31.36%
OM growth 3Y3.8%
OM growth 5Y-6.22%
PM growth 3Y-37.56%
PM growth 5Y-23.7%
GM growth 3Y-8.87%
GM growth 5Y-5.57%
PDEX Yearly Profit, Operating, Gross MarginsPDEX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 20 30

More info and screens

6

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so PDEX is creating value.
Compared to 1 year ago, PDEX has less shares outstanding
PDEX has less shares outstanding than it did 5 years ago.
Compared to 1 year ago, PDEX has an improved debt to assets ratio.
PDEX Yearly Shares OutstandingPDEX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M
PDEX Yearly Total Debt VS Total AssetsPDEX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

PDEX has an Altman-Z score of 6.17. This indicates that PDEX is financially healthy and has little risk of bankruptcy at the moment.
PDEX has a Altman-Z score of 6.17. This is amongst the best in the industry. PDEX outperforms 81.28% of its industry peers.
PDEX has a Debt/Equity ratio of 0.28. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.28, PDEX is in line with its industry, outperforming 49.73% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.28
Debt/FCF N/A
Altman-Z 6.17
ROIC/WACC2.31
WACC8.58%
PDEX Yearly LT Debt VS Equity VS FCFPDEX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M 30M

2.3 Liquidity

A Current Ratio of 2.73 indicates that PDEX has no problem at all paying its short term obligations.
PDEX's Current ratio of 2.73 is in line compared to the rest of the industry. PDEX outperforms 53.48% of its industry peers.
A Quick Ratio of 1.45 indicates that PDEX should not have too much problems paying its short term obligations.
PDEX has a Quick ratio of 1.45. This is in the lower half of the industry: PDEX underperforms 60.96% of its industry peers.
Industry RankSector Rank
Current Ratio 2.73
Quick Ratio 1.45
PDEX Yearly Current Assets VS Current LiabilitesPDEX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

8

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 355.17% over the past year.
PDEX shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -6.76% yearly.
Looking at the last year, PDEX shows a very strong growth in Revenue. The Revenue has grown by 29.65%.
PDEX shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 14.66% yearly.
EPS 1Y (TTM)355.17%
EPS 3Y-17.89%
EPS 5Y-6.76%
EPS Q2Q%331.58%
Revenue 1Y (TTM)29.65%
Revenue growth 3Y12.29%
Revenue growth 5Y14.66%
Sales Q2Q%21.84%

3.2 Future

The Earnings Per Share is expected to grow by 97.88% on average over the next years. This is a very strong growth
PDEX is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 19.04% yearly.
EPS Next Y278.39%
EPS Next 2Y97.88%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year35.63%
Revenue Next 2Y19.04%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
PDEX Yearly Revenue VS EstimatesPDEX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 20M 40M 60M
PDEX Yearly EPS VS EstimatesPDEX Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0.5 1 1.5 2

More info and screens

5

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 17.51, which indicates a rather expensive current valuation of PDEX.
PDEX's Price/Earnings ratio is rather cheap when compared to the industry. PDEX is cheaper than 82.35% of the companies in the same industry.
PDEX's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 27.29.
A Price/Forward Earnings ratio of 19.04 indicates a rather expensive valuation of PDEX.
PDEX's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. PDEX is cheaper than 79.14% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of PDEX to the average of the S&P500 Index (21.74), we can say PDEX is valued inline with the index average.
Industry RankSector Rank
PE 17.51
Fwd PE 19.04
PDEX Price Earnings VS Forward Price EarningsPDEX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, PDEX is valued cheaper than 87.70% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 12.29
PDEX Per share dataPDEX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

PDEX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of PDEX may justify a higher PE ratio.
A more expensive valuation may be justified as PDEX's earnings are expected to grow with 97.88% in the coming years.
PEG (NY)0.06
PEG (5Y)N/A
EPS Next 2Y97.88%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for PDEX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PRO-DEX INC

NASDAQ:PDEX (7/7/2025, 8:00:00 PM)

After market: 46.22 0 (0%)

46.22

-1.6 (-3.35%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)05-01 2025-05-01/amc
Earnings (Next)09-03 2025-09-03/amc
Inst Owners30.04%
Inst Owner Change0%
Ins Owners35.95%
Ins Owner Change0%
Market Cap150.68M
Analysts82.86
Price Target57.12 (23.58%)
Short Float %7.86%
Short Ratio2.69
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)64.21%
Min EPS beat(2)57.38%
Max EPS beat(2)71.05%
EPS beat(4)4
Avg EPS beat(4)77.71%
Min EPS beat(4)28.85%
Max EPS beat(4)153.55%
EPS beat(8)5
Avg EPS beat(8)9.49%
EPS beat(12)7
Avg EPS beat(12)15.5%
EPS beat(16)7
Avg EPS beat(16)5.1%
Revenue beat(2)1
Avg Revenue beat(2)7.88%
Min Revenue beat(2)-3.54%
Max Revenue beat(2)19.3%
Revenue beat(4)3
Avg Revenue beat(4)18.85%
Min Revenue beat(4)-3.54%
Max Revenue beat(4)38.97%
Revenue beat(8)6
Avg Revenue beat(8)10.51%
Revenue beat(12)10
Avg Revenue beat(12)13.77%
Revenue beat(16)12
Avg Revenue beat(16)10.76%
PT rev (1m)3.7%
PT rev (3m)3.7%
EPS NQ rev (1m)-2.08%
EPS NQ rev (3m)-2.08%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-3.24%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.33%
Valuation
Industry RankSector Rank
PE 17.51
Fwd PE 19.04
P/S 2.35
P/FCF N/A
P/OCF N/A
P/B 4.27
P/tB 4.27
EV/EBITDA 12.29
EPS(TTM)2.64
EY5.71%
EPS(NY)2.43
Fwd EY5.25%
FCF(TTM)-0.54
FCFYN/A
OCF(TTM)-0.15
OCFYN/A
SpS19.67
BVpS10.82
TBVpS10.81
PEG (NY)0.06
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 14.58%
ROE 26.55%
ROCE 25.45%
ROIC 19.83%
ROICexc 25.27%
ROICexgc 25.29%
OM 18.24%
PM (TTM) 14.61%
GM 31.36%
FCFM N/A
ROA(3y)9%
ROA(5y)12.39%
ROE(3y)15.75%
ROE(5y)22.01%
ROIC(3y)11.81%
ROIC(5y)13.41%
ROICexc(3y)13.33%
ROICexc(5y)16.93%
ROICexgc(3y)13.36%
ROICexgc(5y)17.03%
ROCE(3y)15.15%
ROCE(5y)17.2%
ROICexcg growth 3Y11.8%
ROICexcg growth 5Y-12.49%
ROICexc growth 3Y11.98%
ROICexc growth 5Y-12.32%
OM growth 3Y3.8%
OM growth 5Y-6.22%
PM growth 3Y-37.56%
PM growth 5Y-23.7%
GM growth 3Y-8.87%
GM growth 5Y-5.57%
F-Score6
Asset Turnover1
Health
Industry RankSector Rank
Debt/Equity 0.28
Debt/FCF N/A
Debt/EBITDA 0.76
Cap/Depr 102.36%
Cap/Sales 1.96%
Interest Coverage 16.27
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.73
Quick Ratio 1.45
Altman-Z 6.17
F-Score6
WACC8.58%
ROIC/WACC2.31
Cap/Depr(3y)140.73%
Cap/Depr(5y)342.39%
Cap/Sales(3y)2.61%
Cap/Sales(5y)6.21%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)355.17%
EPS 3Y-17.89%
EPS 5Y-6.76%
EPS Q2Q%331.58%
EPS Next Y278.39%
EPS Next 2Y97.88%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)29.65%
Revenue growth 3Y12.29%
Revenue growth 5Y14.66%
Sales Q2Q%21.84%
Revenue Next Year35.63%
Revenue Next 2Y19.04%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y81.9%
EBIT growth 3Y16.56%
EBIT growth 5Y7.53%
EBIT Next Year80%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-7.3%
FCF growth 3YN/A
FCF growth 5Y22%
OCF growth 1Y-11.14%
OCF growth 3YN/A
OCF growth 5Y13.23%